[김창수의 e뉴스 브리핑] Korea-US NASH innovative new drug, Korea New Drug Development Award Technology Export Award, etc.

[FETV=김창수 기자] Hanmi Pharm announced on the 22nd that at the 22nd Korea New Drug Development Awards, which will be held on the 26th,’Epinofegdeutide (LAPSGLP/GCG)’, one of its innovative biopharmaceutical pipelines, will receive the Technology Export Award. Celltrion announced on the 22nd that it recorded 1,8491 trillion won in sales, 7121 billion won in operating profit, and 38.5% operating margin in 2020. Compared to the previous year, sales and operating profit increased by 63.9% and 88.4%, achieving the highest performance ever since the previous year. Dong-A Pharmaceutical announced on the 22nd that it has renewed three kinds of’Gagrin Children’ (apple, strawberry, bubble gum) applied with an eco-friendly package.

◆ Hanmi NASH’s innovative new drug won the Technology Export Award at the Korea New Drug Development Award

An innovative new drug for treatment of NASH (non-alcoholic steatohepatitis), developed by Hanmi Pharmaceutical and exported to MSD in the United States last year, won the Technology Export Award at the Korea New Drug Development Award.

Hanmi Pharm announced on the 22nd that at the 22nd Korea New Drug Development Awards, which will be held on the 26th,’Epinofegdeutide (LAPSGLP/GCG)’, one of its innovative biopharmaceutical pipelines, will receive the Technology Export Award. It is hosted by the New Drug Development Research Association and sponsored by the Ministry of Health and Welfare and the Ministry of Science and Technology Information and Communication.

The Technology Export Award was selected by the Korean New Drug Development Awards Award Review Committee based on the technology level, added value, competitiveness, and contribution to national health improvement of the new drug candidate, and Choi In-young, managing director of Hanmi Pharmaceutical’s bio drug development, represented the company. Participate in the awards ceremony.

◆ “Booming flagship product line” Celltrion, sales of 1.84 trillion won in 2020… 63,9% year-on-year↑

Celltrion announced on the 22nd that it recorded 1,8491 trillion won in sales, 7121 billion won in operating profit, and 38.5% operating margin in 2020. Compared to the previous year, sales and operating profit increased by 63.9% and 88.4%, achieving the highest performance ever since the previous year.

In the case of the fourth quarter of last year, sales increased by 30.3% and operating profit by 44.3% compared to the same period last year, with sales of 4987 billion won and operating profit of 16.4 billion won.

Celltrion explained that last year’s expansion of the biosimilar product line resulted in an increase in supply and improved production efficiency at the expansion facility of the first plant, which resulted in good results. The flagship product line maintained a solid market share in the European market with Remsima 52.8%, Truxima 38%, and Herzuma 15.9% in the third quarter of last year. In the US market, Inflectra (Remsima export name to the US) 11.8% and Truxima 19.8% as of the fourth quarter of last year.

◆ Dong-A Pharmaceutical launches a renewal for Gagrin children with eco-friendly packages

Dong-A Pharmaceutical announced on the 22nd that it has renewed three kinds of’Gagrin Children’ (apple, strawberry, bubble gum) applied with an eco-friendly package.

The newly changed Gagrin children’s use has eco-friendly elements such as an in-mold label that is easy to recycle. In-mold labels reduce product adhesion chemicals, making label removal easier. By visualizing the tear-off mark, consumers were encouraged to increase the recycling rate by removing the label. Earlier in 2019, the container containing Gagrin was also changed to be transparent.

In addition, to emphasize the importance of protecting endangered animals, a total of nine species of endangered species, including half-moon black bears and eagle owls, were included in the design. It plans to use part of the proceeds from sales as a fund to protect endangered species.

◆ Dr. G, released 3 types of weakly acidic cleansing products

Gowoon Sesang Cosmetic’s derma cosmetic brand’Doctor G’has renewed and launched three mild, weakly acidic cleansing products that make skin healthy.

Dr.G’s weakly acidic cleansing line is a hypoallergenic cleansing solution that contains skin barrier protection ingredients for healthy skin.It has been renovated through three kinds of ingredients: ▲Weakly Acidic Cleansing Gel Foam, ▲Weakly Acidic Cleansing Water ▲Weakly Acidic Cleansing Oil. With this, the lineup of Dr.G’s weakly acidic products has been further strengthened with a total of 4 types, including the existing’Weakly Acidic Red Blemish Clear Soothing Foam’.

In particular, all of the newly released weakly acidic cleansing products contain 5-biome ingredients that are beneficial to the skin, protecting the barrier and helping maintain healthy skin condition. In addition, it is a pH weakly acidic formula similar to the skin barrier, so anyone with sensitive skin can use it, and clean, mild cleansing such as sun cream and fine dust is possible.

◆ Shillazen investors, “April by-election, vote for candidates to solve problems”

The Shillazen activist shareholders’ meeting (CEO Seong-ho Lee), a group of small shareholders in Shillagen, which has continued to rally for the Sillagen sovereignty trade summit last year at the Blue House, the Democratic Party in Yeouido, and the Korea Exchange, was the first in 2021. On the 23rd, it was announced that a rally to urge the resumption of trading in Shillagen will be held in front of the Korean Exchange in Munhyeon-dong, Busan, centering on individual investors in Shillazen.

Shillazen Busan-Ulsan-Gyeongnam individual investors complained of the unfairness of the Korean Exchange, which deprived them of the exercise of personal property rights on charges of prior listing, and marched through the financial complex in the middle of the rally. It is a plan to intensively inform the citizens of Boo, Ul and Gyeong.